ES2825031T3 - Compuesto heterocíclico sustituido con halógeno útil para el tratamiento de enfermedades causadas por LPA - Google Patents
Compuesto heterocíclico sustituido con halógeno útil para el tratamiento de enfermedades causadas por LPAInfo
- Publication number
- ES2825031T3 ES2825031T3 ES18157384T ES18157384T ES2825031T3 ES 2825031 T3 ES2825031 T3 ES 2825031T3 ES 18157384 T ES18157384 T ES 18157384T ES 18157384 T ES18157384 T ES 18157384T ES 2825031 T3 ES2825031 T3 ES 2825031T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- cyclopropanecarboxylic
- carbonyl
- ethoxy
- biphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *S(C#C/C(/F)=C\C=C)N Chemical compound *S(C#C/C(/F)=C\C=C)N 0.000 description 23
- GHAQHNRGIVYLMS-SBYNAHCQSA-N C/C=C(\C=C/C(I)=C)/N Chemical compound C/C=C(\C=C/C(I)=C)/N GHAQHNRGIVYLMS-SBYNAHCQSA-N 0.000 description 1
- LKINGAHMOLWTEM-UHFFFAOYSA-N CC(c(cc(cc1)F)c1F)SC Chemical compound CC(c(cc(cc1)F)c1F)SC LKINGAHMOLWTEM-UHFFFAOYSA-N 0.000 description 1
- AJSVGADOOSNSER-UHFFFAOYSA-N CC(c1c[s]cc1)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O Chemical compound CC(c1c[s]cc1)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O AJSVGADOOSNSER-UHFFFAOYSA-N 0.000 description 1
- QWPVJTANZAORBP-UHFFFAOYSA-N CC(c1c[s]cc1)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(F)c1)=O Chemical compound CC(c1c[s]cc1)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(F)c1)=O QWPVJTANZAORBP-UHFFFAOYSA-N 0.000 description 1
- MWJUEDMZAKLZPT-UHFFFAOYSA-N CC(c1c[s]cc1C)=O Chemical compound CC(c1c[s]cc1C)=O MWJUEDMZAKLZPT-UHFFFAOYSA-N 0.000 description 1
- BJVKDXLSEMDAHR-UHFFFAOYSA-N CC(c1n[s]cc1)O Chemical compound CC(c1n[s]cc1)O BJVKDXLSEMDAHR-UHFFFAOYSA-N 0.000 description 1
- BPSRDANUOVEDGJ-LJQANCHMSA-N CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(cc1)ccc1F)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(cc1)ccc1F)=O)=O BPSRDANUOVEDGJ-LJQANCHMSA-N 0.000 description 1
- UFPWJQAGTBXWGX-GOSISDBHSA-N CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(Cl)c1)c1N[IH](O[C@H](C)c(ccc(F)c1)c1F)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(Cl)c1)c1N[IH](O[C@H](C)c(ccc(F)c1)c1F)=O)=O UFPWJQAGTBXWGX-GOSISDBHSA-N 0.000 description 1
- HOKTYHXKLFRPQN-UHFFFAOYSA-N CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(F)c1)c1C(O)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(F)c1)c1C(O)=O)=O HOKTYHXKLFRPQN-UHFFFAOYSA-N 0.000 description 1
- SEFQOTNUOAMHBI-GOSISDBHSA-N CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(ccc(F)c1)c1F)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(ccc(F)c1)c1F)=O)=O SEFQOTNUOAMHBI-GOSISDBHSA-N 0.000 description 1
- OHUSVRSTTNRBMV-UHFFFAOYSA-N CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]cc1)c1NC(OC(C)c(cccc1)c1Cl)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]cc1)c1NC(OC(C)c(cccc1)c1Cl)=O)=O OHUSVRSTTNRBMV-UHFFFAOYSA-N 0.000 description 1
- ZFCBZMUATBCFOA-UHFFFAOYSA-N CCOC(C1(CC1)c(cc1)ccc1-c(nc1)ccc1-c([s]c(Cl)c1)c1NC(OC(C)c1c[s]cc1)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(nc1)ccc1-c([s]c(Cl)c1)c1NC(OC(C)c1c[s]cc1)=O)=O ZFCBZMUATBCFOA-UHFFFAOYSA-N 0.000 description 1
- VADIOMHYKBBYFU-UHFFFAOYSA-N CC[O](C)C(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(F)c1)c1NC(OC1(CC1)c1cc(F)ccc1F)=O)=O Chemical compound CC[O](C)C(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(F)c1)c1NC(OC1(CC1)c1cc(F)ccc1F)=O)=O VADIOMHYKBBYFU-UHFFFAOYSA-N 0.000 description 1
- QTTAKXPPGQAQPS-UHFFFAOYSA-N CCc1c(CS)cccc1 Chemical compound CCc1c(CS)cccc1 QTTAKXPPGQAQPS-UHFFFAOYSA-N 0.000 description 1
- WSPNDBJBDXXENM-UHFFFAOYSA-N C[BrH]c([s]c(Cl)c1)c1C(N)=O Chemical compound C[BrH]c([s]c(Cl)c1)c1C(N)=O WSPNDBJBDXXENM-UHFFFAOYSA-N 0.000 description 1
- HIHYQVLDBDIJMA-MRXNPFEDSA-N C[C@H](c(cc1)ccc1F)OC(Nc1c(-c(cc2)cc([N+]([O-])=O)c2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O Chemical compound C[C@H](c(cc1)ccc1F)OC(Nc1c(-c(cc2)cc([N+]([O-])=O)c2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O HIHYQVLDBDIJMA-MRXNPFEDSA-N 0.000 description 1
- PGDLDMGUQGOJNK-QGZVFWFLSA-N C[C@H](c(cccc1)c1Cl)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O Chemical compound C[C@H](c(cccc1)c1Cl)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O PGDLDMGUQGOJNK-QGZVFWFLSA-N 0.000 description 1
- GCKDPEFZAJOXTO-QGZVFWFLSA-N C[C@H](c(cccc1)c1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(F)c1)=O Chemical compound C[C@H](c(cccc1)c1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(F)c1)=O GCKDPEFZAJOXTO-QGZVFWFLSA-N 0.000 description 1
- POPPMARFOMSRID-ZCFIWIBFSA-N C[C@H](c(cccc1)c1F)O[IH](N)=O Chemical compound C[C@H](c(cccc1)c1F)O[IH](N)=O POPPMARFOMSRID-ZCFIWIBFSA-N 0.000 description 1
- MZUQRPNKUOLTDS-MRXNPFEDSA-N C[C@H](c1cc(F)ccc1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O Chemical compound C[C@H](c1cc(F)ccc1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O MZUQRPNKUOLTDS-MRXNPFEDSA-N 0.000 description 1
- XLEYEBMEAHFQFM-UHFFFAOYSA-N NC(C1)C=CC(c2ccc(C3(CC3)C(O)=O)cc2)=C1C(O)=O Chemical compound NC(C1)C=CC(c2ccc(C3(CC3)C(O)=O)cc2)=C1C(O)=O XLEYEBMEAHFQFM-UHFFFAOYSA-N 0.000 description 1
- BSKSBZFKDXXZEV-UHFFFAOYSA-N NC(c1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(C(O)=O)c2)[s]cc1)O Chemical compound NC(c1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(C(O)=O)c2)[s]cc1)O BSKSBZFKDXXZEV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012286425 | 2012-12-28 | ||
| JP2013097171 | 2013-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2825031T3 true ES2825031T3 (es) | 2021-05-14 |
Family
ID=51021433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18157384T Active ES2825031T3 (es) | 2012-12-28 | 2013-12-27 | Compuesto heterocíclico sustituido con halógeno útil para el tratamiento de enfermedades causadas por LPA |
| ES13868493.1T Active ES2667798T3 (es) | 2012-12-28 | 2013-12-27 | Compuesto heterocíclico sustituido con halógeno |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13868493.1T Active ES2667798T3 (es) | 2012-12-28 | 2013-12-27 | Compuesto heterocíclico sustituido con halógeno |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10000463B2 (OSRAM) |
| EP (2) | EP3360869B1 (OSRAM) |
| JP (3) | JP6176258B2 (OSRAM) |
| KR (1) | KR102189166B1 (OSRAM) |
| CN (2) | CN107698555B (OSRAM) |
| AU (1) | AU2013366898B2 (OSRAM) |
| BR (1) | BR112015015275B1 (OSRAM) |
| CA (1) | CA2896701C (OSRAM) |
| DK (2) | DK3360869T3 (OSRAM) |
| ES (2) | ES2825031T3 (OSRAM) |
| MX (1) | MX369801B (OSRAM) |
| RU (2) | RU2649398C2 (OSRAM) |
| WO (1) | WO2014104372A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014104372A1 (ja) * | 2012-12-28 | 2014-07-03 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
| BR112015023267B1 (pt) | 2013-03-15 | 2023-01-31 | Epigen Biosciences, Inc | Composto, e medicamento para tratar um indivíduo com doença ou condição lisofosfatídica dependente de ácido |
| JP2014231508A (ja) * | 2013-05-02 | 2014-12-11 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
| ES2824801T3 (es) * | 2014-06-27 | 2021-05-13 | Ube Industries | Sal de compuesto heterocíclico sustituido con halógeno |
| RU2018122224A (ru) * | 2015-11-20 | 2019-12-25 | Убе Индастриз, Лтд. | Фармацевтическая композиция для лечения или предупреждения nash |
| CN114206832B (zh) * | 2019-07-30 | 2025-04-04 | 大正制药株式会社 | 拮抗lpa1受体的脲化合物 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| AU2021282986B2 (en) | 2020-06-03 | 2024-03-07 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN111909170B (zh) * | 2020-09-11 | 2022-08-12 | 吉林奥来德光电材料股份有限公司 | 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件 |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| JP7709612B2 (ja) | 2021-12-08 | 2025-07-16 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| CA3222642A1 (en) | 2022-12-12 | 2024-06-12 | Bmic Llc | Downstream uses for briquettes and other forms of powder from asphalt shingle waste |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6964975B2 (en) | 2000-02-18 | 2005-11-15 | Kirin Beer Kabushiki Kaisha | Isoxazole and thiazole compounds and use thereof as medicine |
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| WO2005012269A1 (ja) * | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| BRPI0920825A2 (pt) | 2008-09-29 | 2015-12-22 | Lilly Co Eli | modulador seletivo do receptor de estrogênio |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011091167A2 (en) | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| WO2011159632A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
| WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| CA2820817A1 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| US9556133B2 (en) | 2010-12-07 | 2017-01-31 | Bristol-Myers Squibb Company | Polycyclic LPA1 antagonist and uses thereof |
| EP2694496A1 (en) | 2011-04-05 | 2014-02-12 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| PH12014500355A1 (en) | 2011-08-15 | 2014-03-31 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
| WO2014104372A1 (ja) * | 2012-12-28 | 2014-07-03 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
-
2013
- 2013-12-27 WO PCT/JP2013/085277 patent/WO2014104372A1/ja not_active Ceased
- 2013-12-27 ES ES18157384T patent/ES2825031T3/es active Active
- 2013-12-27 CN CN201710949188.8A patent/CN107698555B/zh active Active
- 2013-12-27 DK DK18157384.1T patent/DK3360869T3/da active
- 2013-12-27 CA CA2896701A patent/CA2896701C/en active Active
- 2013-12-27 CN CN201380068911.1A patent/CN104884447B/zh active Active
- 2013-12-27 KR KR1020157019230A patent/KR102189166B1/ko active Active
- 2013-12-27 DK DK13868493.1T patent/DK2940013T3/en active
- 2013-12-27 MX MX2015008479A patent/MX369801B/es active IP Right Grant
- 2013-12-27 BR BR112015015275-9A patent/BR112015015275B1/pt active IP Right Grant
- 2013-12-27 AU AU2013366898A patent/AU2013366898B2/en active Active
- 2013-12-27 RU RU2015131139A patent/RU2649398C2/ru active
- 2013-12-27 ES ES13868493.1T patent/ES2667798T3/es active Active
- 2013-12-27 EP EP18157384.1A patent/EP3360869B1/en active Active
- 2013-12-27 JP JP2014554626A patent/JP6176258B2/ja active Active
- 2013-12-27 RU RU2018109925A patent/RU2756506C2/ru active
- 2013-12-27 EP EP13868493.1A patent/EP2940013B1/en active Active
-
2015
- 2015-06-26 US US14/752,623 patent/US10000463B2/en active Active
-
2017
- 2017-07-11 JP JP2017135811A patent/JP6414286B2/ja active Active
-
2018
- 2018-05-08 US US15/974,494 patent/US10597375B2/en active Active
- 2018-10-03 JP JP2018188246A patent/JP6569792B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2825031T3 (es) | Compuesto heterocíclico sustituido con halógeno útil para el tratamiento de enfermedades causadas por LPA | |
| AU2014275643B2 (en) | Heterocyclic derivatives and use thereof | |
| JP6648137B2 (ja) | ヘテロ環式誘導体およびその使用 | |
| RU2733750C2 (ru) | Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение | |
| EP3162801B1 (en) | Salt of halogen-substituted heterocyclic compound | |
| US20190092761A1 (en) | Methods and Compositions for Inhibition of Bromodomain and Extratermial Proteins | |
| CA2506799A1 (en) | Mixed lineage kinase modulators | |
| WO2014151682A1 (en) | Pyrimidine compounds as kinase inhibitors | |
| CA3012812A1 (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
| CN104334528A (zh) | (2-杂芳基氨基)琥珀酸衍生物 | |
| JP6216326B2 (ja) | 炎症および癌の処置において有用なビスアリールスルホンアミド | |
| WO2017018495A1 (ja) | シクロプロパン誘導体及びそれを含有する医薬 | |
| WO2025011632A1 (zh) | 含四氢苯并[4,5]呋喃[2,3-c]吡啶类羟肟酸化合物及其制备方法和应用 | |
| CN106795173A (zh) | 作为ftl3和jak抑制剂的大环n‑芳基‑2‑氨基‑4‑芳基‑嘧啶聚醚的衍生物 | |
| RU2542980C2 (ru) | Замещенные производные 3-бензофуранил-индол-2-он-3-ацетамидопиперазинов, их получение и их применение в терапии | |
| CN108358939A (zh) | 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途 | |
| CA3220193A1 (en) | Novel oxazole derivative and pharmaceutical composition for preventing or treating allergic diseases comprising the same | |
| CN118852164A (zh) | Parp选择性抑制剂 | |
| AU2006269015A1 (en) | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | |
| BR112017011312B1 (pt) | Composto, composição farmacêutica e uso do composto | |
| HK1165216A (en) | Process for the preparation of alogliptin |